Skip to main content
. 2017 Sep 15;6(11):1540–1550. doi: 10.1016/j.molmet.2017.08.013

Figure 8.

Figure 8

Phenotypes of mice with Brs3 re-expression in Vglut2- or Vgat-expressing neurons. Groups are: WT, Brs3-/y (KO), Brs3loxTB/y (loxTB), Brs3loxTB/y;Vglut2-Cre (Vglut2-Cre), and Brs3loxTB/y;Vgat-Cre (Vgat-Cre) mice. Mice in A–L were fed a HFD and M–O were on chow. (A–C) Glucose tolerance test, area under the curve (AUC) of glucose tolerance test, and insulin at 0 and 15 min after glucose challenge. (D, E) Insulin tolerance test and area under the curve (AUC) of insulin tolerance test. (F) Fasting blood glucose. (G–I) Serum leptin, triglyceride (TG), cholesterol, and free fatty acid (FFA) levels. (J–L) Body weight, length, and tissue weights at 25 weeks (N = 5 WT, 5 KO, 19 loxTB, 10 Vglut2-Cre, 6 Vgat-Cre). Levels not sharing a letter are different at P < 0.05 determined by 1-way ANOVA with Holm-Sidak post-hoc testing. (M–N) Two-hour food intake after treatment with vehicle or MK-5046 (10 mg/kg, i.p) or MTII (3 mg/kg, i.p.) (N = 3–7/group). (O) Effect of MK-5046 (10 mg/kg, i.p.) on energy expenditure (N = 4–7/group). * indicates P < 0.05, drug vs vehicle, within genotype.